Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exact Sciences Corp.

Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Second-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences schedules second quarter 2024 earnings call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in June Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Earns 2024 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces First-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Schedules First Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.